| Date | Title | Description | Source |
| 06.03.2024 | Apellis Pharmaceuticals Announces Inducement Grants Under Na... | - | globenewsw... |
| 30.11.2022 | Prevent Blindness Declares Second Annual Geographic Atrophy ... | Prevent Blindness declares Dec. 5-11, 2022, as the second annual Geographic Atrophy Awareness Week, ... | prweb.com/... |
| 26.01.2022 | Prevent Blindness Declares February as Age-related Macular D... | Prevent Blindness declares February as Age-related Macular Degeneration (AMD), and Low Vision Awaren... | prweb.com/... |
| 15.12.2021 | Aspaveli® (pegcetacoplan) approved in EU as orphan drug for ... | Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH Wed, Dec 15, 2021 13:00... | news.cisio... |
| 13.12.2021 | Aspaveli®/Empaveli™ (pegcetacoplan) demonstrated sustained n... | Improvements demonstrated in treatment-naïve patients and patients with baseline haemoglobin levels ... | marketscre... |
| 13.12.2021 | Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrat... | Improvements demonstrated in treatment-naïve patients and patients with baseline hemoglobin levels g... | marketscre... |
| 01.12.2021 | Prevent Blindness Declares First-ever Geographic Atrophy Awa... | National non-profit organization, Prevent Blindness, declares Dec. 6-12, 2021, as first-ever Geograp... | prweb.com/... |
| 12.11.2021 | Apellis Reiterates Plans to Submit a New Drug Application in... | WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today... | marketscre... |
| 15.10.2021 | Swedish Orphan Biovitrum : Aspaveli® (pegcetacoplan) receive... | Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: ... | marketscre... |
| 09.09.2021 | Apellis Pharmaceuticals : Announces Top-Line Results from Ph... | OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, d... | marketscre... |
| 26.07.2021 | Apellis Pharmaceuticals : Announces Closing of Previously An... | Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Princ... | marketscre... |
| 26.07.2021 | Apellis Pharmaceuticals : Announces Closing of Previously An... | WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a glo... | marketscre... |
| 08.07.2021 | Apellis Announces Agreements to Exchange Approximately $198.... | WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a glo... | marketscre... |
| 05.11.2020 | Apellis Pharmaceuticals : to Present New Data Supporting the... | Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate ... | marketscre... |
| 11.06.2020 | What being stricken with Covid-19 taught a biotech CEO | On March 14, at 10 a.m., I got the call that I had tested positive for SARS-CoV-2, the virus that ca... | statnews.c... |
| 16.03.2020 | Two biotech CEOs test positive for Covid-19 after attending ... | On Friday evening, Allogene CEO Arie Belldegrun posted a statement on Twitter stating that he had co... | medcitynew... |
| 14.11.2017 | Epidarex Capital Portfolio Company Apellis Pharmaceuticals C... | Epidarex Capital, an early-stage, transatlantic life science venture fund, is pleased to announce th... | citybizlis... |
| 10.11.2017 | Term Sheet — Friday, November 10 | HOT TAKES
Happy Friday, Term Sheet readers.
Paid Content Securing the enterprise without boundaries ... | fortune.co... |
| 31.10.2017 | Term Sheet — Tuesday, October 31 | DEAD AND GONE
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see?... | fortune.co... |
| 16.10.2017 | Term Sheet — Monday, October 16 | MONDAY KICKOFF
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see Fr... | fortune.co... |
| 10.08.2017 | Apellis Pharmaceuticals Announces $60M Series E Financing | - | sofinnova.... |
| 10.08.2017 | Apellis Pharmaceuticals Raises $60M in Series E Financing | Apellis Pharmaceuticals, Inc., a Lousiville, Ky.-based clinical-stage biopharmaceutical company deve... | finsmes.co... |
| 12.02.2016 | Apellis Completes $47M Series D Financing |
LOUISVILLE, KY, Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 milli... | vcnewsdail... |
| 12.02.2016 | Apellis Pharmaceuticals Completes $47.1M Series D Financing | Apellis Pharmaceuticals, Inc., a Louisville, Ky.-based clinical stage biopharmaceutical company, com... | finsmes.co... |
| 12.02.2016 | Apellis raises $47M after pulling the plug on an $86M IPO | Apellis CEO Cedric Francois
Louisville, KY, drug developer Apellis Pharmaceuticals raised $47.1 mill... | fiercebiot... |
| 02.12.2014 | Apellis Pharmaceuticals Raises $33M |
LOUISVILLE, KY, Leading biotechnology company applying immunotherapy to autoimmune disease, today ... | vcnewsdail... |
| 02.12.2014 | Immunotherapy player Apellis Pharmaceuticals raises $33M | -COPD. Apellis thinks the same C3 inhibitor could slow down the progression of this chronic lung dis... | medcitynew... |
| 28.08.2014 | Apellis Pharma raises $17.6M; focuses on asthma and COPD | Apellis is developing complement inhibitors to break the immunological cycle that prevents the human... | medcitynew... |
| 05.04.2013 | Move over bats and bourbon, healthcare startups are taking o... | Bob Saunders, an angel investor and one of the founders of the accelerator, said that this effort wi... | medcitynew... |
| 02.08.2012 | Biopharma led by transplant expert raising up to $3M for sev... | Location: Crestwood, Kentucky.
Solution/product: To address chronic inflammatory diseases, starting ... | medcitynew... |
| - | Immunotherapy player Apellis Pharmaceuticals raises $33M | Apellis Pharmaceuticals just raised $33M to fund exploring its immunotherapy platform in three dispa... | medcitynew... |
| - | Biopharma led by transplant expert raising up to $3M for sev... | Company name: Apellis Pharmaceuticals Inc.
Industry: Pharmaceuticals.
Location: Crestwood, Kentucky.... | medcitynew... |
| - | Apellis Pharma raises $17.6M; focuses on asthma and COPD | Kentucky-based biotech Apellis Pharmaceuticals is raising a nice chunk of change – $17.6 million, ac... | medcitynew... |
| - | Two biotech CEOs test positive for Covid-19 after attending ... | The Covid-19 pandemic hit home for the biotechnology community earlier this month when Biogen disclo... | medcitynew... |
| - | Move over bats and bourbon, healthcare startups are taking o... | A new accelerator wants to bring healthcare startups in Louisville, Kentucky, onto the national rada... | medcitynew... |
